Gilead (GILD) director awarded RSUs and options as 224 shares withheld for taxes

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Gilead Sciences director Harish Manwani reported routine equity compensation and related tax withholding. He received 1,146 restricted stock units, which vested immediately and increased his direct common stock holdings to 15,239 shares after the grant.

He also received a non-qualified stock option for 4,884 shares of common stock at an exercise price of $130.84 per share, fully vested on April 30, 2026 and expiring in 2036. Separately, 224 shares were withheld at $130.84 per share to cover tax obligations, a non‑market, tax-withholding disposition rather than an open-market sale.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider MANWANI HARISH

Role null

Type	Security	Shares	Price	Value
Grant/Award	Non-qualified Stock Option (Right to Buy)	4,884	$0.00	--
Grant/Award	Common Stock	1,146	$0.00	--
Tax Withholding	Common Stock	224	$130.84	$29K

Holdings After Transaction: Non-qualified Stock Option (Right to Buy) — 4,884 shares (Direct, null); Common Stock — 15,239 shares (Direct, null)

Footnotes (1)

Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026. 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Key Figures

Tax-withheld shares: 224 shares RSU grant: 1,146 shares Option grant size: 4,884 shares +3 more

6 metrics

Tax-withheld shares 224 shares Common stock withheld at $130.84 per share for taxes

RSU grant 1,146 shares Restricted stock units vested immediately on April 30, 2026

Option grant size 4,884 shares Non-qualified stock option for common stock

Option exercise price $130.84 per share Strike price of non-qualified stock option

Shares held after RSU grant 15,239 shares Direct common stock holdings following RSU acquisition

Option expiration April 30, 2036 Expiration date of non-qualified stock option

Key Terms

restricted stock units ("RSUs"), Non-qualified Stock Option (Right to Buy), 2022 Equity Incentive Plan, tax-withholding disposition

4 terms

restricted stock units ("RSUs") financial

"Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Non-qualified Stock Option (Right to Buy) financial

"security_title: "Non-qualified Stock Option (Right to Buy)" for 4,884.0000 shares."

2022 Equity Incentive Plan financial

"RSUs granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan."

tax-withholding disposition financial

"transaction_action: "tax-withholding disposition" for 224.0000 shares at $130.8400."

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Form 4 Insider Transactions: What Each Field Means →

05/04/2026 - 04:20 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MANWANI HARISH

(Last)

(First)

(Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY

CALIFORNIA

94404

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock⁽¹⁾	04/30/2026		A		1,146	A	$0	15,239	D
Common Stock	04/30/2026		F		224	D	$130.84	15,015	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-qualified Stock Option (Right to Buy)	$130.84	04/30/2026		A		4,884		⁽²⁾	04/30/2036	Common Stock	4,884	$0	4,884	D

Explanation of Responses:

1. Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

2. 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Remarks:

	/s/ Amy Kim by Power of Attorney for Harish Manwani	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Gilead (GILD) director Harish Manwani report in this Form 4?

Harish Manwani reported routine equity compensation and tax withholding. He received 1,146 vested RSUs and a fully vested option for 4,884 shares, while 224 shares of common stock were withheld to satisfy tax obligations tied to these awards.

How many Gilead (GILD) shares does Harish Manwani hold after these transactions?

After the reported transactions, Harish Manwani directly holds 15,239 shares of Gilead common stock. This reflects the immediate vesting and settlement of 1,146 RSUs, net of 224 shares withheld to cover associated tax liabilities on April 30, 2026.

What equity awards did Harish Manwani receive from Gilead (GILD)?

He received 1,146 restricted stock units and a non-qualified stock option for 4,884 shares at a $130.84 exercise price. Both awards were granted under the 2022 Equity Incentive Plan and vested immediately on April 30, 2026, according to the filing footnotes.

Was there an open-market sale of Gilead (GILD) stock in this Form 4?

No open-market sale occurred. The 224-share disposition was a tax-withholding event, where shares were delivered to cover tax liabilities. This differs from selling shares on the market and is treated as a mechanistic, compensation-related transaction, not an active sale decision.

What are the key terms of Harish Manwani’s Gilead (GILD) stock option grant?

The non-qualified stock option covers 4,884 Gilead common shares at a $130.84 exercise price. All shares under the option vested immediately on April 30, 2026, and the option expires on April 30, 2036, giving a long exercise window for the director.